RecruitingPhase 2NCT05978505

Reboxetine for Sleep Apnoea After ENT Surgery

Reboxetine for Obstructive Sleep Apnoea After Upper Airway Surgery: a Randomised, Double-blind, Placebo-controlled Study


Sponsor

Flinders University

Enrollment

20 participants

Start Date

Aug 10, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This pilot study will establish the feasibility of a larger trial to investigate whether reboxetine, a medication used to treat depression, can reduce the severity of obstructive sleep apnea (OSA) including increased blood oxygenation in post-surgical OSA patients where positive airway pressure (CPAP) therapy is either frequently poorly tolerated or not an option immediately post surgery. In this randomized, placebo-controlled, double-blind study, participants will use at-home sleep monitoring equipment before and after surgery plus measures of oxygenation. They will be prescribed either reboxetine or a placebo for seven days after surgery and complete questionnaires at the beginning and end of the study.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Reboxetine 4 MG Oral Tablet for people with sleep apnea, obstructive. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGReboxetine 4 MG Oral Tablet

7 nightly doses (4mg) to commence after surgery.

DRUGPlacebo

7 nightly doses to commence after surgery.


Locations(1)

Flinders, Private and Public Hospitals and Flinders University

Bedford Park, South Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05978505


Related Trials